Condensed Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net loss	$ (13,064)	$ (6,019)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	48	20
Stock-based compensation expense	746	21
Amortization of intangible assets	11
Loss on disposition of property and equipment		8
Change in fair value of preferred stock warrants		888
Change in fair value of common stock warrants	1,177
Inducement charge for Series C warrants	3,050
Non-cash expense of issuing shares to Aspire Capital	183
Non-cash interest expense relating to warrants and convertible promissory notes		1,811
Change in operating assets and liabilities:
Accounts receivable	(94)	112
Inventories	(267)
Prepaid expenses and other assets	27	(101)
Accounts payable	542	103
Accrued liabilities	720	229
Net cash used in operating activities	(6,921)	(2,928)
Cash flows from investing activities:
Cash paid for purchase of assets of NeoForce Group, Inc.	(1,000)
Increase in restricted cash	(91)
Cash paid for patent acquisition	(150)
Purchase of property and equipment	(48)
Net cash (used in) provided by investing activities	(1,289)
Cash flows from financing activities:
Proceeds from issuance of common stock	1,434
Proceeds from exercise of common stock options	294
Proceeds from issuance of convertible notes payable		1,999
Initial public offering costs paid	(530)	(276)
Repayment of credit line	(102)
Net cash provided by financing activities	4,973	1,723
Net increase (decrease) in cash and cash equivalents	(3,237)	(1,205)
Cash and cash equivalents, beginning of period	7,957	1,269
Cash and cash equivalents, end of period	4,720	$ 64
Supplemental disclosures of noncash investing and financing information
Patent costs included in Accrued liabilities	300
Reduction in initial public offering costs payable	45
Cashless exercise of 2010/2012 warrants	13
Issuance of 50,000 shares of Common Stock as consideration for patent acquisition	112
Series A Warrant Liability [Member]
Cash flows from financing activities:
Proceeds from exercise of warrants	156
Series A Warrant Liability [Member] | Cash Exercise [Member]
Supplemental disclosures of noncash investing and financing information
De-recognition warrant liability	42
Private Placement Series B Warrants [Member]
Cash flows from financing activities:
Proceeds from exercise of warrants	3,832
Tender Offer Series B Warrants [Member]
Cash flows from financing activities:
Proceeds from exercise of warrants	6
Other Series B Warrants [Member]
Cash flows from financing activities:
Proceeds from exercise of warrants	189
Series B Warrant Liability [Member]
Cash flows from financing activities:
Series B warrant transaction costs paid	(306)
Supplemental disclosures of noncash investing and financing information
De-recognition warrant liability	9,500
Series B Warrant Liability [Member] | Cash Exercise [Member]
Supplemental disclosures of noncash investing and financing information
De-recognition warrant liability	6,747
Series B Warrant Liability [Member] | Cash Less Exercise [Member]
Supplemental disclosures of noncash investing and financing information
De-recognition warrant liability	9,475
Series B Warrant Liability [Member] | Warrants contributed back to the Company [Member]
Supplemental disclosures of noncash investing and financing information
De-recognition warrant liability	$ 3